122 related articles for article (PubMed ID: 38648575)
1. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR; Dowlati A; Chen Y; Navarro A; Yang JC; Stojanovic G; Jove M; Rich P; Andric ZG; Wu YL; Rudin CM; Chen H; Zhang L; Yeung S; Benzaghou F; Paz-Ares L; Bunn PA;
J Clin Oncol; 2024 Apr; ():JCO2302110. PubMed ID: 38648575
[TBL] [Abstract][Full Text] [Related]
2. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares L; Spigel DR; Chen Y; Jove M; Juan-Vidal O; Rich P; Hayes T; Calderón VG; Caro RB; Navarro A; Dowlati A; Zhang B; Moore Y; Yao X; Kokhreidze J; Ponce S; Bunn PA
Cancer; 2022 May; 128(9):1801-1811. PubMed ID: 35195913
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
4. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
5. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
7. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N; Hao Z; Villaruz LC; Zhang J; Ruiz J; Petty WJ; Mamdani H; Riess JW; Nieva J; Pachecho JM; Fuld AD; Shum E; Chauhan A; Nichols S; Shimellis H; McGlone J; Sciuto L; Pinkiert D; Graham C; Shelat M; Kattappuram R; Abel M; Schroeder B; Upadhyay D; Krishnamurthy M; Sharma AK; Kumar R; Malin J; Schultz CW; Goyal S; Redon CE; Pommier Y; Aladjem MI; Gore SD; Steinberg SM; Vilimas R; Desai P; Thomas A
JAMA Oncol; 2023 Dec; 9(12):1669-1677. PubMed ID: 37824137
[TBL] [Abstract][Full Text] [Related]
8. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
9. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
10. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.
Aktas G; Kus T; Kalender ME; Sevinc A; Camci C; Kul S
Onco Targets Ther; 2016; 9():1921-6. PubMed ID: 27099522
[TBL] [Abstract][Full Text] [Related]
11. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
12. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis.
Shi H; Guo N; Zhao Z; Liu L; Ni T; Zhang J; Lu Y
Front Oncol; 2023; 13():1154685. PubMed ID: 37007093
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
15. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
Hacibekiroglu I; Ozkul O; Cakir E; Kostek O; Karatas F; Esenkaya A; Demirci A; Bilir C
J BUON; 2021; 26(1):79-86. PubMed ID: 33721436
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
